

TARO PHARMACEUTICALS INC.

BALANCE SHEETS

	March 31, 2022 (Unaudited) USD Dollars	March 31, 2021 (Unaudited) USD Dollars
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 203,847,761	\$ 503,905,780
Short-term bank deposits	\$ -	-
Marketable securities	\$ 458,173,271	368,645,237
Trade accounts receivable	\$ 27,675,129	19,150,768
Other receivables and prepaid expenses:		
Prepaid expenses	3,534,501	3,343,949
Deferred income taxes	-	-
Government authorities	9,736,622	13,647,944
Advances to suppliers	25,538	923,548
Derivative instruments	87,357	8,898
Intercompany balances	261,754,489	255,713,073
Other	6,772,862	4,556,664
TOTAL Other receivables and prepaid expenses	281,911,368	278,194,076
Inventories	76,329,069	83,566,748
TOTAL CURRENT ASSETS	1,047,936,599	1,253,462,609
LONG-TERM RECEIVABLES AND OTHER ASSETS	362,624,039	468,170,971
FIXED ASSETS:		
Cost	121,570,138	115,557,450
Less - accumulated depreciation	(64,421,193)	(58,136,494)
	57,148,945	57,420,956
GOODWILL	276,147	276,147
INTANGIBLE ASSETS AND DEFERRED COSTS, NET	79,675,201	89,811,083
INVESTMENT IN ASSOCIATED COMPANIES	367,117,780	-
DEFERRED INCOME TAXES	34,939,078	49,380,411
TOTAL ASSETS	\$ 1,949,717,789	\$ 1,918,522,176

TARO PHARMACEUTICALS INC.

BALANCE SHEETS

	March 31, 2022 (Unaudited) USD Dollars	March 31, 2021 (Unaudited) USD Dollars
LIABILITIES AND SHAREHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Accounts payable:		
Trade payables	\$ 28,748,586	\$ 30,422,106
Other current liabilities:		
Returns reserve	7,897,462	5,606,604
Due to customers	-	-
Intercompany balances	4,260,069	963,825
Employees and payroll accruals	5,334,189	4,953,626
Deferred revenue	236,624	236,624
Medicaid and indirect rebates	6,664,628	2,048,110
Accrued income taxes	-	-
Legal and audit fees	-	-
Accrued expenses	10,452,918	25,942,872
Interest payable	-	-
Derivative instruments	180,601	-
Deferred taxes	-	-
Other	322,226	383,043
TOTAL Other current liabilities	35,348,717	40,134,704
TOTAL CURRENT LIABILITIES	64,097,303	70,556,810
LONG-TERM LIABILITIES:		
Deferred income taxes	-	-
Other long-term liabilities	24,481,509	31,433,034
	24,481,509	31,433,034
SHAREHOLDERS' EQUITY	1,861,138,977	1,816,532,332
	\$ 1,949,717,789	\$ 1,918,522,176

Date of approval of the
financial statements

Thurga S. Mayuran
Director, Finance

TARO PHARMACEUTICALS INC.

STATEMENTS OF INCOME

	For the year Ended March 31, 2022 (Unaudited) USD Dollars	For the year Ended March 31, 2021 (Unaudited) USD Dollars	For the year Ended March 31, 2020 (Unaudited) USD Dollars
Sales	\$ 288,772,111	\$ 259,636,042	\$ 355,823,117
Cost of sales	169,630,345	177,495,026	149,030,163
Gross profit	119,141,765	82,141,016	206,792,955
Research and development	19,598,992	23,401,899	24,424,343
Selling and marketing expenses	10,750,192	10,389,199	10,193,400
General and administrative expenses	8,100,916	8,806,004	7,341,255
Operating income	80,691,666	39,543,915	164,833,957
Settlements and Loss Contingencies	18,623,673	62,254,128	-
Financing income (expenses), net	9,327,570	17,659,106	44,407,893
Other income (expense)	60,911	906,567	1,587,436
Income before taxes on income	71,456,473	(4,144,541)	210,829,286
Taxes on income	12,994,735	(12,713,298)	55,934,860
Net income for the period before subsidiaries and dividend	58,461,738	8,568,757	154,894,427
Dividend income, net	-	-	-
Subsidiaries	-	-	-
Net income for the period	\$ 58,461,738	\$ 8,568,757	\$ 154,894,427

TARO PHARMACEUTICALS INC.

Changes in Shareholders' Equity

CAD/USD Dollars

Unaudited

	Number of Shares (Unaudited)	Share Capital (Unaudited)	Additional Paid-in Capital (Unaudited)	Accumulated Other Comprehensive Income (Loss) (Unaudited)	Foreign Currency Translation Adj (Unaudited)	Retained Earnings (Unaudited)	Total Taro Shareholders' Equity (Unaudited)	Noncontrolling Interest (Unaudited)	Total Shareholders' Equity (Unaudited)
Balance at March 31, 2019 (CAD)	11	230,338,690	295,107	17,999,918	-	1,703,932,868	1,952,566,584	-	1,952,566,584
Balance at March 31, 2019 (USD)	11	173,200,008	263,098	13,512,438	(156,753,284)	1,432,483,995	1,462,706,254	-	1,462,706,254
Reduction of shares issued to TNA	0.9	199,407,236	-	-	-	-	199,407,236	-	199,407,236
Comprehensive income, net of tax	-	-	-	(17,029,108)	-	-	(17,029,108)	-	(17,029,108)
Net income	-	-	-	-	-	154,894,427	154,894,427.00	-	154,894,427
Balance at March 31, 2020 (USD)	12	372,607,244	263,098	(3,516,670)	(156,753,284)	1,587,378,422	1,799,978,810	-	1,799,978,810
Comprehensive income, net of tax	-	-	-	7,984,764	-	-	7,984,764	-	7,984,764
Net income	-	-	-	-	-	8,568,758	8,568,758.00	-	8,568,758
Balance at March 31, 2021 (USD)	12	372,607,244	263,098	4,468,094	(156,753,284)	1,595,947,180	1,816,532,332	-	1,816,532,332
Comprehensive income, net of tax	-	-	-	(13,855,093)	-	-	(13,855,093)	-	(13,855,093)
Net income (loss)	-	-	-	-	-	58,461,738	58,461,738	-	58,461,738
Balance at March 31, 2022 (USD)	12	372,607,244	263,098	(9,386,999)	(156,753,284)	1,654,408,918	1,861,138,977	-	1,861,138,977